Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin
- 21 June 2022
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (6), e0021522
- https://doi.org/10.1128/aac.00215-22
Abstract
Dolutegravir-based regimens are recommended as first-line therapy for HIV in low- and middle-income countries where tuberculosis is the most common opportunistic infection. Concurrent HIV/tuberculosis treatment is challenging because of drug-drug interactions. Our analysis aimed to characterize dolutegravir's population pharmacokinetics when coadministered with rifampicin and assess alternative dolutegravir dosing regimens. We developed a population pharmacokinetic model of dolutegravir in NONMEM with data from two healthy-volunteer studies (RADIO and ClinicalTrials.gov identifier NCT01231542) and validated it with data from the INSPIRING study, which consisted of participants living with HIV. The model was developed with 817 dolutegravir plasma concentrations from 41 participants. A 2-compartment model with first-order elimination and lagged absorption best described dolutegravir's pharmacokinetics. For a typical 70-kg individual, we estimated a clearance, absorption rate constant, central volume, and peripheral volume of 1.03 L/h, 1.61 h(-1), 12.7 L, and 3.85 L, respectively. Rifampicin coadministration increased dolutegravir clearance by 144% (95% confidence interval [CI], 126 to 161%). Simulations showed that when 50 or 100 mg once-daily dolutegravir is coadministered with rifampicin in 70-kg individuals, 71.7% and 91.5% attain trough concentrations above 0.064 mg/L, the protein-adjusted 90% inhibitory concentration (PA-IC90), respectively. The model developed from healthy-volunteer data describes patient data reasonably well but underpredicts trough concentrations. Although 50 mg of dolutegravir given twice daily achieves target concentrations in more than 99% of individuals cotreated with rifampicin, 100 mg of dolutegravir, once daily, in the same population is predicted to achieve satisfactory pharmacokinetic target attainment. The efficacy of this regimen should be investigated since it presents an opportunity for treatment simplification.Funding Information
- Pharmacometrics Africa NPC
- UNITAID
- ViiV Healthcare
This publication has 27 references indexed in Scilit:
- Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With RifabutinJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase InhibitorDrug Metabolism and Disposition, 2012
- Effect of Food on the Pharmacokinetics of the Integrase Inhibitor DolutegravirAntimicrobial Agents and Chemotherapy, 2012
- Mechanism-Based Concepts of Size and Maturity in PharmacokineticsAnnual Review of Pharmacology and Toxicology, 2008
- Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studiesJournal of Pharmacokinetics and Pharmacodynamics, 2007
- A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first‐pass hepatic extractionBritish Journal of Clinical Pharmacology, 2005
- Quantification of Lean BodyweightClinical Pharmacokinetics, 2005
- The Influence of Sex on PharmacokineticsClinical Pharmacokinetics, 2003
- Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3AAntimicrobial Agents and Chemotherapy, 2001
- Nutritional status and weight gain in patients with pulmonary tuberculosis in TanzaniaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1996